ANGES

AnGes MG, Inc. is a biopharmaceutical company with a mission to provide patients, especially those suffering from disease for which no effective therapy has been available to date, with innovative drugs. AnGes focuses on development of gene medicine, a next-generation biopharmaceutical. AnGes MG, Inc. was founded in December 1999 on an innovative discovery by researchers at Osaka University. AnGes already went through the first stage of research and development and is now in the second stage ... of commercialization. “Naglazyme®,” a drug for the treatment of mucopolysaccharidosis VI, an intractable disease, has already been marketed in Japan and HGF Plasmid (gene therapy) for the treatment of critical limb ischemia, which is a serious impairment of blood circulation in the legs, is in the last stage of clinical development. Development of “NF-κB decoy oligonucleotide,” a nucleic acid medicine that suppresses various types of inflammation including atopic dermatitis, disc degeneration, and medical device for prevention of vascular restenosis is also under way. Having started from research and development and now embarking on the new stage of practical application, AnGes strives to fulfill the expectations of patients, their families, shareholders, investors and the general public waiting for new drugs to be available and aims at becoming a “global leader in the field of gene medicine.”
ANGES
Social Links:
Industry:
Biopharma Biotechnology Genetics Health Care
Founded:
1999-01-01
Address:
Tokyo, Tokyo, Japan
Country:
Japan
Website Url:
http://www.anges.co.jp
Total Employee:
51+
Status:
Active
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Euro SPF Apple Mobile Web Clips Icon Google Tag Manager Google Analytics Amazon SSL By Default Global Site Tag
Similar Organizations
Enzyvant Sciences
Enzyvant Sciences is a biotechnology company which focuses on developing treatments for rare diseases.
Mast Therapeutics
Mast Therapeutics is a biopharmaceutical company developing novel, clinical-stage therapies for serious or life-threatening diseases.
Soligenix
Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.
Watsin
Watsin is a high-tech biopharmaceutical company engaged in the R&D of gene engineering medicine.
Current Advisors List
Current Employees Featured
Stock Details
Acquisitions List
Date | Company | Article | Price |
---|---|---|---|
2020-12-15 | EmendoBio, Inc. | EmendoBio, Inc. acquired by AnGes | 250 M USD |
Investors List
Biofrontier Partners
Biofrontier Partners investment in Seed Round - AnGes
Investments List
Date | Company | Article | Money raised |
---|---|---|---|
2020-12-15 | EmendoBio, Inc. | AnGes investment in Corporate Round - EmendoBio, Inc. | 250 M USD |
2020-01-15 | EmendoBio, Inc. | AnGes investment in Series B - EmendoBio, Inc. | 61 M USD |
2018-08-15 | MyBiotics Pharma LTD | AnGes investment in Series A - MyBiotics Pharma LTD | 8 M USD |
2015-04-10 | FunPep | AnGes investment in Venture Round - FunPep | 25.6 M JPY |
2005-08-12 | Dolthera GmbH | AnGes investment in Series B - Dolthera GmbH | 14.5 M EUR |
Official Site Inspections
http://www.anges.co.jp Semrush global rank: 2.07 M Semrush visits lastest month: 9.9 K
Unable to get host informations!!!

More informations about "AnGes"
AnGes, Inc.
AnGes , Inc. is a biopharmaceutical company with the mission of providing patients suffering from diseases for which no effective therapy has been available to date, with innovative drugs. …See details»
アンジェス - Wikipedia
アンジェス株式会社 は、 遺伝子医薬 開発を行う日本のバイオ製薬企業。そのファイナンスの姿勢から、株券印刷業者とも呼ばれている [1][2]。See details»
AnGes - Crunchbase Company Profile & Funding
AnGes is a biopharmaceutical company specialized in HGF plasmid, NFkB decoy oligonucleotide, and therapeutic vaccines.See details»
AnGes - businessabc
Feb 18, 2025 AnGes was founded in 2000 in Tokyo, Japan. The company has since gone on to become one of the largest and most respected biotech companies in the country. AnGes has …See details»
【アンジェス】 [4563]企業概要 社員数や役員報酬・資本金 | 日経 …
【日本経済新聞】アンジェス [4563]の企業概要。役員人事や社員数、資本金に関する情報から関連会社や取引先、監査法人などあらゆる知りたい ...See details»
AnGes Company Profile - Office Locations, Competitors, Revenue …
Oct 29, 2024 AnGes has 5 employees across 6 locations and ¥152.98 m in annual revenue in FY 2023. See insights on AnGes including office locations, competitors, revenue, financials, …See details»
企業調査 - 株式会社フィスコ
になることを目指している。新薬候補品を開発し、販売パートナーとの販売権許諾契約によって得られる契約一時金や、開発の進捗状況等によって得られるマイルストーン収入、上市後の …See details»
AnGes Company Profile | Management and Employees List
May 20, 2014 AnGes Profile and History AnGes, Inc., a biopharmaceutical company, engages in the research and development of gene-based medical products. Its lead product is Hepatocyte …See details»
AnGes, Inc. | Shared Research
Since the company’s establishment in 1999, HGF gene therapy drug (a new drug candidate; regenerates blood vessels by medicating HGF—hepatocyte growth factor—genes) has been …See details»
AnGes Inc Company Profile - AnGes Inc Overview - GlobalData
Up-to-date AnGes Inc company overview including funding information, company profile, key statistics, peer comparison and more.See details»
企業調査 - 株式会社フィスコ
で、欧米では販売承認済み。HGPSやPLは遺伝子の突然変異で発症し、症状としては深刻な成長障害、強皮症に似た皮膚、全身性脂肪性筋萎縮症、脱毛症、骨格形成不全、動脈硬化の促進 …See details»
Company AnGes, Inc. Other OTC - MarketScreener.com
AnGes, Inc., formerly AnGes MG, Inc., is a Japan-based company mainly engaged in the development of genetic medicines. The Company is involved in the development of …See details»
日 会社 ¡ アンジェス株式会社 2025 年1 月15日 各 位 会社名 アン …
当社は、2022年9月7日に「改良型 DNA ワクチンの経鼻投与製剤に関する米国スタンフォード大学との共同研究契約の締結について」において公表いたしました共同研究の成果として、新 …See details»
AnGes, Inc. (4563.T) - Yahoo Finance
Find the latest AnGes, Inc. (4563.T) stock quote, history, news and other vital information to help you with your stock trading and investing.See details»
AnGes, Inc. (AnGes, Inc.) - 药物管线_专利_临床试验_投融营收_最新 …
了解AnGes, Inc. (AnGes, Inc.)公司的药物管线,治疗领域,技术平台,以及它的18项临床试验, 25篇新闻和16篇文献,疾病领域:内分泌与代谢疾病,感染,肿瘤,血液及淋巴系统疾病,免 …See details»
EPS Group co-develops COVID-19 vaccine with Osaka University …
EPS Group co-develops COVID-19 vaccine with Osaka University and AnGes Co., Ltd. as a contract research organization EPS Group entered into a development collaboration of DNA …See details»
企業調査 - 株式会社フィスコ
になることを目指している。新薬候補品を開発し、販売パートナーとの販売権許諾契約によって得られる契約一時金や、開発の進捗状況などによって得られるマイルストーン収入、上市後 …See details»
AnGes open for partnership to remain a hero in gene therapy
Feb 3, 2019 “AnGes looks forward to a future of improving human health and quality of life through pioneering in the development of innovative medicines,” says president and CEO Dr …See details»
営業外収益及び営業外 - anges.co.jp
1.営業外収益の計上 1補助金収入 当社と共同開発契約を締結しているカナダのバイオ医薬品企業であるVasomune Therapeutics Inc. が、急性呼吸窮迫症候群(ARDS) を標的とする同社の主 …See details»